JP2006526031A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526031A5
JP2006526031A5 JP2006519178A JP2006519178A JP2006526031A5 JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5 JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5
Authority
JP
Japan
Prior art keywords
represented
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006519178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2004/007562 external-priority patent/WO2004103369A1/en
Publication of JP2006526031A publication Critical patent/JP2006526031A/ja
Publication of JP2006526031A5 publication Critical patent/JP2006526031A5/ja
Pending legal-status Critical Current

Links

JP2006519178A 2003-05-26 2004-05-26 ヒストンデアセチラーゼ阻害物質を含む医薬組成物 Pending JP2006526031A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (2)

Publication Number Publication Date
JP2006526031A JP2006526031A (ja) 2006-11-16
JP2006526031A5 true JP2006526031A5 (https=) 2006-12-28

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519178A Pending JP2006526031A (ja) 2003-05-26 2004-05-26 ヒストンデアセチラーゼ阻害物質を含む医薬組成物

Country Status (27)

Country Link
US (1) US20070098816A1 (https=)
EP (1) EP1626719A1 (https=)
JP (1) JP2006526031A (https=)
KR (1) KR100938712B1 (https=)
CN (2) CN101322707A (https=)
AR (1) AR045318A1 (https=)
AU (1) AU2004241873C1 (https=)
BR (1) BRPI0410959A (https=)
CA (4) CA2634766A1 (https=)
CL (1) CL2004001278A1 (https=)
CO (1) CO5660262A2 (https=)
CR (1) CR8163A (https=)
CU (1) CU23490B7 (https=)
EC (1) ECSP056253A (https=)
IL (1) IL171941A0 (https=)
ME (1) MEP32308A (https=)
MX (1) MXPA05012345A (https=)
NO (1) NO20055417L (https=)
NZ (1) NZ543591A (https=)
PE (1) PE20050206A1 (https=)
RS (1) RS20050884A (https=)
RU (1) RU2322971C2 (https=)
TW (1) TW200505424A (https=)
UA (1) UA81499C2 (https=)
UY (1) UY28330A1 (https=)
WO (1) WO2004103369A1 (https=)
ZA (1) ZA200509515B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20080234265A1 (en) * 2005-03-11 2008-09-25 The Regents Of The University Of Colorado Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
AU2007214458C1 (en) 2006-02-14 2012-12-06 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
RU2446796C2 (ru) * 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PE20141062A1 (es) * 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
ES2663222T3 (es) 2008-12-19 2018-04-11 Vertex Pharmaceuticals Incorporated Derivados de pirazina útiles como inhibidores de la quinasa ATR
WO2010093561A1 (en) * 2009-02-11 2010-08-19 Liangping Yu Particulate composition and the method of making the same
US20120128667A1 (en) * 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049859A1 (en) * 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
MX2017003463A (es) 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
CA2342981A1 (en) * 1998-09-25 2000-04-06 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
WO2001034131A2 (en) * 1999-11-10 2001-05-17 Warner-Lambert Company Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Similar Documents

Publication Publication Date Title
JP2006526031A5 (https=)
JP2006515626A5 (https=)
JP2007522220A5 (https=)
JP2005518413A5 (https=)
JP2009535462A5 (https=)
JP2010501534A5 (https=)
JP2009545527A5 (https=)
JP2007503202A5 (https=)
JP2008506632A5 (https=)
JP2010536766A5 (https=)
JP2009502743A5 (https=)
JP2014515013A5 (https=)
JP2005053931A5 (https=)
JP2006240292A5 (https=)
JP2006503588A5 (https=)
JP2008513510A5 (https=)
JP2005522505A5 (https=)
JP2010530897A5 (https=)
JP2010521514A5 (https=)
JP2010520214A5 (https=)
JP2007510619A5 (https=)
JP2007519721A5 (https=)
JP2010507590A5 (https=)
JP2010534246A5 (https=)
JP2006518752A5 (https=)